サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1119777

インスリン製剤およびデリバリー技術の世界市場

Global Markets for Insulin Drug and Delivery Technologies
出版日: | 発行: BCC Research | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
インスリン製剤およびデリバリー技術の世界市場
出版日: 2022年08月19日
発行: BCC Research
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のインスリン製剤およびデリバリー技術の市場規模は、2022年に558億米ドルになるとみられています。

同市場は、2022年～2027年の予測期間中に9.8%のCAGRで拡大し、2027年には889億米ドルに達すると予測されています。

当レポートでは、世界のインスリン製剤およびデリバリー技術市場について調査し、市場の概要とともに、装置タイプ別、インスリンタイプ別、地域別動向、COVID-19の影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 まとめとハイライト

第3章 市場力学

  • 市場促進要因
  • 糖尿病の有病率の上昇
  • スマートインスリンドラッグデリバリー技術
  • 無痛インスリンドラッグデリバリー技術
  • 市場の抑制要因
  • 製品のリコール
  • 市場の機会
  • 市場関係者の無機的戦略

第4章 市場概要

  • 市場の洞察
  • インスリン
  • 糖尿病
  • 現在の市場動向
  • 最近の製品紹介
  • 最近の戦略的提携
  • 将来の展望

第5章 規制状況と償還のシナリオ

  • 規制状況
  • 米国の医薬品規制
  • 欧州の医薬品規制
  • アジア太平洋の医療機器規制

第6章 COVID-19の市場への影響

第7章 デバイスタイプ別市場内訳

  • インスリンデリバリー技術
  • シリンジ
  • インスリンペン
  • インスリンポンプ
  • スマートペン
  • その他

第8章 インスリンタイプ別市場内訳

  • インスリン
  • インスリンの構造
  • インスリンの生合成
  • インスリンタイプ

第9章 地域別市場内訳

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 市場の機会分析

第11章 競合情勢

第12章 企業プロファイル

  • 主要企業
  • B. BRAUN MELSUNGEN AG
  • BECTON, DICKINSON AND CO.
  • BIOCON
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • MEDTRONIC INC.
  • NOVO NORDISK A/S
  • SANOFI
  • VIATRIS INC.
  • YPSOMED HOLDING AG
  • Other Companies
  • CEQUR SIMPLICITY
  • DEBIOTECH SA
  • EMPERRA GMBH E-HEALTH TECHNOLOGIES
  • INSULET CORP.
  • NANOPASS TECHNOLOGIES LTD.
  • NIPRO MEDICAL CORP.
  • OWEN MUMFORD LTD.
  • TANDEM DIABETES CARE INC.

第13章 付録：頭字語

図表

List of Tables

  • Summary Table : Global Market for Insulin Drug and Delivery Technologies, by Device Type, Through 2027
  • Table 1 : Cases of Diabetes Worldwide, by Type
  • Table 2 : Global Prevalence of Diabetes, by Type, Through 2040
  • Table 3 : Global Diabetes Estimates and Projections, 2019-2045
  • Table 4 : History of Insulin Isolation and Development
  • Table 5 : Currently Available Insulin Brands
  • Table 6 : Features of Type 1 and Type 2 Diabetes
  • Table 7 : Strategic Alliances in the Market for Insulin Drug and Delivery Technologies, 2020-2022
  • Table 8 : Insulin Drug and Delivery Technologies Pipeline
  • Table 9 : Global Market for Insulin Drug and Delivery Technologies, by Device Type, Through 2027
  • Table 10 : Advantages and Disadvantages of Syringes
  • Table 11 : Global Market for Syringe Delivery Technologies, by Region, Through 2027
  • Table 12 : Advantages and Disadvantages of Insulin Pens
  • Table 13 : Global Market for Insulin Pen Delivery Technologies, by Region, Through 2027
  • Table 14 : Advantages and Disadvantages of Insulin Pumps
  • Table 15 : Global Market for Insulin Pump Delivery Technologies, by Region, Through 2027
  • Table 16 : Global Market for Smart Insulin Pen Delivery Technologies, by Region, Through 2027
  • Table 17 : Global Market for Other Types of Delivery Technologies, by Region, Through 2027
  • Table 18 : Advantages and Disadvantages of Various Insulin Delivery Systems
  • Table 19 : Types of Insulin and Their Features
  • Table 20 : Global Market for Insulin Drug and Delivery Technologies, by Insulin Type, Through 2027
  • Table 21 : Global Market for Long-acting Insulin, by Region, Through 2027
  • Table 22 : Global Market for Rapid-acting Insulin, by Region, Through 2027
  • Table 23 : Global Market for Intermediate-acting Insulin, by Region, Through 2027
  • Table 24 : Global Market for Short-acting Insulin, by Region, Through 2027
  • Table 25 : Global Market for Premixed Insulin, by Region, Through 2027
  • Table 26 : Global Market for Insulin Drug and Delivery Technologies, by Region, Through 2027
  • Table 27 : Diabetes Estimates in North America, by Country, 2000-2045
  • Table 28 : North American Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
  • Table 29 : Diabetes Estimates in Europe, by Country, 2000-2045
  • Table 30 : European Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
  • Table 31 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
  • Table 32 : Asia-Pacific Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
  • Table 33 : Diabetes Estimates in the RoW, by Country, 2000-2045
  • Table 34 : Porter's Five Forces Analysis: Insulin Drug and Delivery Technologies Market
  • Table 35 : B. Braun Melsungen: Insulin Drug and Delivery Product Portfolio
  • Table 36 : BD: Insulin Drug and Delivery Product Portfolio
  • Table 37 : Biocon: Insulin Product Portfolio
  • Table 38 : Biocon: Key Developments, 2020-2021
  • Table 39 : Boehringer Ingelheim: Insulin Product Portfolio
  • Table 40 : Eli Lilly: Insulin Products
  • Table 41 : Eli Lilly: Key Developments, 2020-2021
  • Table 42 : F. Hoffmann-La Roche: Insulin Drug and Delivery Product Portfolio
  • Table 43 : F. Hoffmann-La Roche: Key Developments, 2021
  • Table 44 : Medtronic: Insulin Drug and Delivery Products Portfolio
  • Table 45 : Medtronic: Key Developments, 2020-2021
  • Table 46 : Novo Nordisk: Insulin Drug and Delivery Products Portfolio
  • Table 47 : Novo Nordisk: Key Developments, 2018-2022
  • Table 48 : Sanofi: Insulin Drug and Delivery Products Portfolio
  • Table 49 : Sanofi: Key Developments, 2018-2021
  • Table 50 : Viatris: Insulin Drug and Delivery Products Portfolio
  • Table 51 : Viatris: Key Developments, 2021
  • Table 52 : Ypsomed Holding AG: Insulin Drug and Delivery Products Portfolio
  • Table 53 : Ypsomed Holding AG: Key Developments, 2020-2022
  • Table 54 : Acronyms Used in This Report

List of Figures

Figure A : Timeline of Major Insulin Breakthroughs

  • Summary Figure A : Global Insulin Drug and Delivery Technologies Market
  • Summary Figure B : Global Market Shares of Insulin Drug and Delivery Technologies, by Device Type, 2021
  • Figure 1 : Cases of Diabetes Worldwide, by Type
  • Figure 2 : Global Prevalence of Diabetes, by Type, 2018-2040
  • Figure 3 : Medical Device Marketing Process in the U.S.
  • Figure 4 : Global Market Shares of Insulin Delivery Technologies, 2021 and 2027
  • Figure 5 : Global Market for Syringes Delivery Technologies, 2020-2027
  • Figure 6 : Global Market for Insulin Pen Delivery Technologies, 2020-2027
  • Figure 7 : Global Market for Insulin Pump Delivery Technologies, 2020-2027
  • Figure 8 : Global Market for Smart Insulin Pen Delivery Technologies, 2020-2027
  • Figure 9 : Global Market for Other Types of Delivery Technologies, 2020-2027
  • Figure 10 : Global Market Shares of Insulin Drug and Delivery Technologies, by Insulin Type, 2021 and 2027
  • Figure 11 : Global Market for Long-acting Insulin, 2020-2027
  • Figure 12 : Global Market for Rapid-acting Insulin, 2020-2027
  • Figure 13 : Global Market for Intermediate-acting Insulin, 2021-2027
  • Figure 14 : Global Market for Short-acting Insulin, 2020-2027
  • Figure 15 : Global Market for Premixed Insulin, 2020-2027
  • Figure 16 : Snapshot of Global Market for Insulin Drug and Delivery Technologies, 2021
  • Figure 17 : Global Market Shares of Insulin Drug and Delivery Technologies, by Region, 2021
  • Figure 18 : Snapshot of North American Market for Insulin Drug and Delivery Technologies, 2021
  • Figure 19 : North American Market for Insulin Drug and Delivery Technologies, by Country, 2021-2027
  • Figure 20 : Snapshot of European Market for Insulin Drug and Delivery Technologies, 2021
  • Figure 21 : European Market for Insulin Drug and Delivery Technologies, by Country, 2020-2027
  • Figure 22 : European Market Shares of Insulin Drug and Delivery Technologies, by Country, 2021
  • Figure 23 : Snapshot of Asia-Pacific Market for Insulin Drug and Delivery Technologies, 2021
  • Figure 24 : Asia-Pacific Market for Insulin Drug and Delivery Technologies, by Country, 2021-2027
  • Figure 25 : Asia-Pacific Market Shares of Insulin Drug and Delivery Technologies, by Country, 2021
  • Figure 26 : Global Market Shares of Insulin Drug and Delivery Technologies, by Company, 2021
  • Figure 27 : B. Braun Melsungen: Annual Revenue, 2018-2021
  • Figure 28 : B. Braun Melsungen: Revenue Share, by Division, 2021
  • Figure 29 : BD: Annual Revenue, 2018-2021
  • Figure 30 : BD: Revenue Share, by Business Segment, 2021
  • Figure 31 : Boehringer Ingelheim: Annual Revenue, 2018-2021
  • Figure 32 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
  • Figure 33 : Eli Lilly: Annual Revenue, 2018-2021
  • Figure 34 : F. Hoffmann-La Roche: Annual Revenue, 2018-2021
  • Figure 35 : F. Hoffmann-La Roche: Revenue Share, by Division, 2021
  • Figure 36 : Medtronic: Annual Revenue, 2018-2021
  • Figure 37 : Medtronic: Revenue Share, by Business Segment, 2021
  • Figure 38 : Novo Nordisk: Annual Revenue, 2018-2021
  • Figure 39 : Novo Nordisk: Revenue Share, by Business Segment, 2021
  • Figure 40 : Sanofi: Annual Revenue, 2018-2021
  • Figure 41 : Sanofi: Revenue Share, by Business Unit, 2021
  • Figure 42 : Viatris: Annual Revenue, 2018-2021
  • Figure 43 : Viatris: Revenue Share, by Product Category, 2020
  • Figure 44 : Ypsomed Holding AG: Annual Revenue, 2018-2021
  • Figure 45 : Ypsomed Holding AG: Revenue Share, by Business Unit, 2021
目次
Product Code: HLC149B

Highlights:

The global market for insulin drug and delivery technologies is estimated to increase from $55.8 billion in 2022 to reach $88.9 billion by 2027, at a compound annual growth rate (CAGR) of 9.8% from 2022 through 2027.

The global market for syringe delivery technologies is estimated to increase from $24.3 billion in 2022 to reach $37.0 billion by 2027, at a CAGR of 8.7% from 2022 through 2027.

The global market for smart insulin pen delivery technologies is estimated to increase from $4.2 billion in 2022 to reach $7.7 billion by 2027, at a CAGR of 12.6% from 2022 through 2027.

Report Scope:

The current report will provide an in-depth look at the insulin drug and delivery technologies market. This report analyzes the market trends of insulin drug and delivery technologies with data from 2021, estimates from 2022, projections of compound annual growth rates through 2027 (forecast period 2022-2027), and regional markets of the insulin drug and delivery technologies. This report will highlight the current and future market potential of insulin drug and delivery technologies along with a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints and opportunities will be covered in the current report. The report also covers market projections for 2026 and market share for key market players.

In this report, the market has been segmented based on device type, insulin type and geographic region. Device types include syringes, insulin pens, insulin pumps, smart pens and others. Insulin types include long-acting, rapid-acting, premixed insulins, intermediate-acting and short-acting.

Geographic regions covered include North America, Europe, Asia-Pacific and the rest of the world (RoW). Individual countries covered include the U.S., Germany, the U.K., Italy, France, Japan, China and India.

Report Includes:

  • 24 data tables and 31 additional tables
  • An up-to-date review of the global markets for insulin drug and delivery technologies
  • Analyses of the global market trends, with historic market revenue (sales data) for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current state of the insulin drug and delivery industry structure, novel technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
  • Estimation of the actual market size and market forecast for insulin drug and delivery technologies, and corresponding market share analysis by device type, insulin type, and geographic region
  • Updated information on the key merger and acquisition deals, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technologies industry
  • Analysis of market opportunities with a holistic review of the Porter's Five Forces analysis model considering both the micro and macro environmental factors prevailing in the market
  • Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
  • Descriptive company profiles of key manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG

Table of Contents

Chapter 1 Introduction

  • 1.1 Insulin Overview
  • 1.2 Diabetes Overview
    • 1.2.1 Disease Symptoms and Risk Factors
    • 1.2.2 Epidemiology and Economic Burden
  • 1.3 Study Goals and Objectives
  • 1.4 Reasons for Doing this Study
  • 1.5 What's New in this Update?
  • 1.6 Scope of Report
  • 1.7 Information Sources
  • 1.8 Methodology
  • 1.9 Geographic Breakdown
  • 1.10 Analyst's Credentials
  • 1.11 BCC Custom Research
  • 1.12 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Rising Prevalence of Diabetes
    • 3.1.2 Smart Insulin Drug Delivery Technologies
    • 3.1.3 Painless Insulin Drug Delivery Technologies
  • 3.2 Market Restraints
    • 3.2.1 Product Recalls
  • 3.3 Market Opportunities
    • 3.3.1 Inorganic Strategies amongst Market Players

Chapter 4 Market Overview

  • 4.1 Market Insights
    • 4.1.1 Insulin
    • 4.1.2 Diabetes
  • 4.2 Current Market Trends
    • 4.2.1 Recent Product Introductions
    • 4.2.2 Recent Strategic Alliances
  • 4.3 Future Perspective

Chapter 5 Regulatory Landscape and Reimbursement Scenario

  • 5.1 Regulatory Landscape
    • 5.1.1 U.S. Regulations for Medical Devices
    • 5.1.2 U.S. Drug Regulations
    • 5.1.3 European Regulations for Medical Devices
    • 5.1.4 European Regulations for Drugs
    • 5.1.5 Asia-Pacific Regulations for Medical Devices
  • 5.2 Reimbursement Scenario
    • 5.2.1 Pricing and Reimbursement Overview
    • 5.2.2 Pricing and Reimbursement for Medical Devices
    • 5.2.3 Pricing and Reimbursement for Pharmaceuticals
  • 5.3 Insurance
    • 5.3.1 Insurance for Diabetic Emergencies

Chapter 6 Impact of COVID-19 on Market

  • 6.1 Overview
  • 6.2 COVID-19 Crisis
    • 6.2.1 Impact on Market for Insulin Drug and Delivery Technologies
    • 6.2.2 COVID-19 Measures

Chapter 7 Market Breakdown by Device Type

  • 7.1 Insulin Delivery Technologies
    • 7.1.1 Syringes
    • 7.1.2 Insulin Pens
    • 7.1.3 Insulin Pumps
    • 7.1.4 Smart Pens
    • 7.1.5 Others

Chapter 8 Market Breakdown by Insulin Type

  • 8.1 Insulin
    • 8.1.1 Structure of Insulin
    • 8.1.2 Insulin Biosynthesis
    • 8.1.3 Insulin Types

Chapter 9 Market Breakdown by Region

  • 9.1 Overview
    • 9.1.1 North America
    • 9.1.2 Europe
    • 9.1.3 Asia-Pacific
    • 9.1.4 Rest of the World

Chapter 10 Analysis of Market Opportunities

  • 10.1 Porter's Five Forces Analysis
    • 10.1.1 Threat of New Entrants
    • 10.1.2 Threat of Substitutes
    • 10.1.3 Bargaining Power of Suppliers
    • 10.1.4 Bargaining Power of Buyers
    • 10.1.5 Degree of Competition

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

  • 12.1 Major Companies
  • B. BRAUN MELSUNGEN AG
  • BECTON, DICKINSON AND CO.
  • BIOCON
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • MEDTRONIC INC.
  • NOVO NORDISK A/S
  • SANOFI
  • VIATRIS INC.
  • YPSOMED HOLDING AG
  • Other Companies
  • CEQUR SIMPLICITY
  • DEBIOTECH SA
  • EMPERRA GMBH E-HEALTH TECHNOLOGIES
  • INSULET CORP.
  • NANOPASS TECHNOLOGIES LTD.
  • NIPRO MEDICAL CORP.
  • OWEN MUMFORD LTD.
  • TANDEM DIABETES CARE INC.

Chapter 13 Appendix: Acronyms